DOD Prostate Cancer Research Program opportunities

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The FY18 Defense Appropriations Act provides $100 million to the Department of Defense Prostate Cancer Research Program to support innovative, high-impact prostate cancer research.

FY18 PCRP Program Announcements and General Application Instructions for the following award mechanisms are posted on Grants.gov.

Applications submitted to the FY18 PCRP must addresses one or more of the Overarching Challenges (revised for FY18):

  • Develop treatments that improve outcomes for men with lethal prostate cancer

  • Reduce lethal prostate cancer in African Americans, Veterans, and other high-risk populations

  • Define the biology of lethal prostate cancer to reduce death

  • Improve the quality of life for survivors of prostate cancer

http://cdmrp.army.mil/funding/pcrp


Health Disparity Research Award

Letter of Intent due Sept. 20


Health Disparity Scholar Award

Letter of Intent due Sept. 20


A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal at https://eBRAP.org prior to the pre-application deadline.

All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.

YOU MAY BE INTERESTED IN

By law, the Food and Drug Administration is required to determine whether a drug, device, biologic, or medical device is “safe and effective.” But the FDA determination does not control whether the Centers for Medicare & Medicaid Services will pay for it.  To satisfy CMS, medical products and services must be “reasonable and necessary,” meaning...

As a radiation oncologist, I am struck by how often the decisive variable in lung cancer is not the sophistication of our therapy, but the timing of our encounter with the disease.  The American Cancer Society projects 618,120 cancer deaths in the United States in 2025, with lung cancer remaining as the single largest contributor,...

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login